
Animal Healthcare Market
Get a free sample of this report
Form submitted successfully!
Error submitting form. Please try again.
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!

Request Sectional Data
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Further, the increasing burden of animal diseases, including chronic and infectious conditions, has also intensified the need for advanced veterinary intervention. Growing incidence of zoonotic diseases, along with the rising human‑animal interface across farms, homes, and urban environments, continues to shape healthcare priorities globally.
The animal healthcare market refers to the global industry focused on the prevention, diagnosis, and treatment of diseases affecting companion and production animals. It encompasses pharmaceuticals, vaccines, diagnostic tools, medicinal feed additives, equipment and disposables that collectively help maintain animal health, enhance livestock productivity, prevent disease outbreaks, and support public health through the reduction of zoonotic risks.
Key players in the animal healthcare market include Zoetis, Merck Animal Health, Boehringer Ingelheim, Elanco Animal Health, Ceva Sante Animale, Virbac, Vetoquinol, Dechra Pharmaceuticals, Neogen Corporation, Phibro Animal Health Corporation, and Biogenesis Bagó. These companies continue to drive innovation through robust R&D pipelines, expansion of vaccine and biologics portfolios, digital diagnostic advancements, and strategic acquisitions aimed at strengthening global manufacturing and distribution networks. Their combined efforts are instrumental in addressing the long‑term healthcare needs of companion animals and livestock populations worldwide.
Between 2022 and 2024, the animal healthcare market experienced steady and sustained growth, supported by the rising adoption of biologics, increased utilization of advanced diagnostics, and strong demand for preventive veterinary care. During this period, the global market expanded from approximately USD 174.2 billion in 2022 to USD 203.3 billion in 2024. Growth was further reinforced by expanding livestock production, increased investment in veterinary pharmaceuticals and broader access to modern veterinary treatments across both developed and emerging markets.
The global animal healthcare market was valued at USD 220.8 billion in 2025. The market is expected to grow from USD 237.8 billion in 2026 to USD 399.4 billion in 2035, at a CAGR of 5.9% during the forecast period, according to the latest report published by Global Market Insights Inc. 

Based on the product, the market is segmented into pharmaceuticals, medical devices, and veterinary services. The veterinary services segment has asserted its dominance in the market by securing a significant revenue share of 74.5% in 2025 and is anticipated to grow at a CAGR of 6% over the forecast years.

Based on animal type, the animal healthcare market is classified as companion animals and livestock animals. The companion animals segment held the highest revenue of USD 133.1 billion in 2025 and is expected to witness a notable growth during the forecast time. The companion animals' segment is sub-segmented into dogs, cats, horses, and other companion animals.
On the other hand, the livestock animals' segment is growing, driven by the rising demand for high‑quality animal protein, increasing prevalence of infectious and production‑limiting diseases, and greater adoption of preventive healthcare practices.

The North America animal healthcare market dominated the global market with a share of 38.5% in 2025.
The U.S. animal healthcare market was valued at USD 26.2 billion and USD 28 billion in 2022 and 2023, respectively. The market size reached USD 32.7 billion in 2025, growing from USD 30.3 billion in 2024.
Europe market accounted for USD 61.5 billion in 2025 and is anticipated to show lucrative growth over the forecast period.
Europe maintains strong momentum due to high pet ownership, established livestock vaccination programs, and widespread availability of veterinary biopharmaceuticals. According to European pet food industry, in Europe, about 90 million households own a pet, stimulating the market demand.
Germany dominates the Europe animal healthcare market, with strong growth potential.
The Asia Pacific market is anticipated to grow at the highest CAGR of 6.3% during the analysis timeframe.
China animal healthcare market is estimated to grow with a significant CAGR, in the Asia Pacific region.
Brazil leads the Latin American animal healthcare industry, exhibiting remarkable growth during the analysis period.
Saudi Arabia animal healthcare industry is expected to experience substantial growth in the Middle East and Africa.
The global animal healthcare industry is characterized by a concentrated yet competitive landscape, with a small group of leading companies generating a substantial share of global revenues. Zoetis, Merck Animal Health, Boehringer Ingelheim, Elanco Animal Health, and IDEXX Laboratories collectively account for approximately 40% of the global market, supported by their broad product portfolios, deep research and development capabilities, and extensive international distribution networks. These companies dominate key therapeutic and diagnostic categories across both livestock and companion animal segments, leveraging leadership in vaccines, pharmaceuticals, parasiticides, diagnostics, and digital veterinary solutions.
Strategic expansion through acquisitions, technology partnerships, and manufacturing investments continues to shape the competitive landscape. For instance, Zoetis has recently strengthened its global production footprint through acquisitions of new manufacturing sites, while Merck Animal Health has expanded its portfolio through targeted M&A activities. Leading companies are actively stimulating development pipelines focused on advanced vaccines, biologics, precision diagnostics, and integrated digital health platforms, driven by rising prevalence of zoonotic diseases, growing pet ownership, and increasing demand for protein-rich livestock products.
Prominent players operating in the animal healthcare industry are as mentioned below:
B. Braun Vet Care (B Braun Melsungen)
Zoetis holds the leading position in the global animal healthcare market, supported by its extensive portfolio spanning vaccines, pharmaceuticals, diagnostics, and genetics for both livestock and companion animals. The company’s strong market presence is reinforced by consistent revenue growth, making it the largest player in the sector. Its leadership is further strengthened by the strategic global expansion of manufacturing facilities to enhance vaccine development and production capacity demonstrating Zoetis continued investment in innovation and global supply capabilities.
Merck Animal Health maintains a strong competitive standing in the global market, driven by its broad-spectrum portfolio of vaccines, pharmaceuticals, and advanced technology platforms designed for both companion animals and livestock. The company continues to invest in next‑generation vaccines, digital platforms, and sustainability-focused initiatives, while leveraging strategic acquisitions such as expanding into specialized segments of animal health to reinforce its long‑term growth and leadership.
Boehringer Ingelheim plays a pivotal role in the global animal healthcare landscape, supported by its research-driven approach and deep expertise in biotechnology, preventive care, and advanced animal therapeutics. Its strong global distribution network and integrated solutions spanning vaccines, biologics, and digital tools allow Boehringer Ingelheim to address growing demand across both livestock and companion animal segments.
| Key Takeaway | Details |
|---|---|
| Market Size & Growth | |
| Base Year | 2025 |
| Market Size in 2025 | USD 220.8 Billion |
| Market Size in 2026 | USD 237.8 Billion |
| Forecast Period 2026-2035 CAGR | 5.9% |
| Market Size in 2035 | USD 399.4 Billion |
| Key Market Trends | |
| Drivers | Impact |
| Increasing population of pet animals | Rising pet adoption globally is boosting demand for veterinary care and health products. |
| Increasing support offered by government and public organizations for animal care | Strengthened policies subsidies and welfare programs are improving access to quality animal healthcare services. |
| Growing demand for online veterinary pharmacies | Expansion of e commerce platforms is enabling convenient access to veterinary medicines and supplements. |
| Increase in animal healthcare expenditure | Higher spending on preventive care diagnostics and advanced treatments is driving market growth. |
| Pitfalls & Challenges | Impact |
| High cost associated with animal health drugs | Premium pricing of vaccines specialty drugs and advanced therapies limits affordability for many pet owners. |
| Limited access in rural areas | Shortage of veterinary professionals and clinics in rural regions restricts timely treatment and disease management. |
| Opportunities: | Impact |
| Expansion of telemedicine and remote veterinary consultation | Growing use of digital platforms will enhance access to veterinary advice and routine care especially in underserved areas. |
| Rising adoption of preventive and wellness focused animal health solutions | Increased focus on diagnostics, nutrition, and early stage disease management offers strong long term growth potential. |
| Market Leaders (2025) | |
| Market Leader |
~11% market share |
| Top Players |
Collective market share in 2025 is ~40% |
| Competitive Edge |
|
| Regional Insights | |
| Largest Market | North America |
| Fastest growing market | Asia Pacific |
| Emerging countries | China, India, Brazil, Mexico, South Africa |
| Future outlook |
|
The animal healthcare market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:
The above information is provided for the following regions and countries:
The market size was valued at USD 220.8 billion in 2025, with a CAGR of 5.9% expected through 2035, driven by rising pet ownership, increasing livestock populations, and growing demand for preventive veterinary care.
The animal healthcare market is expected to reach USD 399.4 billion by 2035, propelled by expanding biologics adoption, digital veterinary innovation, and increased awareness of zoonotic disease prevention globally.
The market size is projected to reach USD 237.8 billion in 2026, supported by rising pet medicalization and accelerating uptake of vaccines, pharmaceuticals, and veterinary services worldwide.
Veterinary services dominated the market with a revenue share of 74.5% in 2025, driven by surging pet adoption rates, and the expanding availability of diagnostic, grooming, boarding, and telemedicine services.
The companion animals segment held the highest revenue of USD 133.1 billion in 2025, fueled by rising global pet ownership and growing launches of advanced animal healthcare products targeting dogs, cats, and horses.
The Asia Pacific animal healthcare market is anticipated to grow at the highest CAGR of 6.3% during the forecast period, driven by rapid improvements in veterinary infrastructure.
North America dominated the global animal healthcare market with a 38.5% share in 2025, valued at USD 32.7 billion in the U.S. alone, supported by high pet care spending and rapid adoption of AI-driven diagnostics and biologics.
Key trends include rising use of biologics and monoclonal antibodies, growth in precision veterinary care, expansion of needle-free treatments, digital livestock innovations, and increasing telemedicine adoption.
Key players include Zoetis, Merck Animal Health, Boehringer Ingelheim, Elanco Animal Health, IDEXX Laboratories, Ceva Sante Animale, Virbac, Vetoquinol, Dechra Pharmaceuticals, Neogen Corporation, Phibro Animal Health, and Indian Immunologicals, among others.
Related Reports
Explore Our Licensing Options: